ResearcherSun Yat-sen UniversityActive in the last 2 years
Xiaoyu Yin
Matched on ORCID iD 0000-0002-5578-3407; OpenAlex author ID A5115601485. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 2, last author 7)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 38
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 12
- The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chem… Last author DOI 10.1186/s12885-026-16353-z↗
- Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
- Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.clinre.2023.102089↗
- Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Last author DOI 10.1016/j.ymthe.2022.11.004↗
- Values of a novel pyroptosis-related genetic signature in predicting outcome and immune status of pancreatic ductal adenocarcinoma. Last author DOI 10.1093/gastro/goac051↗
- Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460. Last author DOI 10.1111/cas.15547↗
- Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.201902926↗
- Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy. Last author DOI 10.1039/d0nr03138k↗
- Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells. First author DOI 10.1177/1533033819895494↗
- WAVE3 promotes proliferation, migration and invasion via the AKT pathway in pancreatic cancer. Co-author DOI 10.3892/ijo.2018.4421↗
- EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway. Last author DOI 10.1016/j.canlet.2016.06.021↗
- Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. First author DOI 10.1158/1940-6207.capr-14-0192↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chen‐Song Huang · 5 shared papers, 2018–2026 · strength 0.76
- Paper The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with REC… DOI 10.1186/s12885-026-16353-z↗
- Paper Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. DOI 10.1016/j.ymthe.2022.11.004↗
- Paper Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma ther… DOI 10.1039/d0nr03138k↗
- Xi‐Tai Huang · 3 shared papers, 2020–2026 · strength 0.52
- Paper The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with REC… DOI 10.1186/s12885-026-16353-z↗
- Paper Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma ther… DOI 10.1039/d0nr03138k↗
- Paper Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic D… DOI 10.1002/advs.201902926↗
- Xiang Xu · 2 shared papers, 2022–2023 · strength 0.47
- Paper Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancr… DOI 10.1016/j.clinre.2023.102089↗
- Paper Values of a novel pyroptosis-related genetic signature in predicting outcome and immune status of pancreatic ductal ade… DOI 10.1093/gastro/goac051↗
- Jie‐Qin Wang · 3 shared papers, 2020–2023 · strength 0.36
- Paper Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. DOI 10.1016/j.ymthe.2022.11.004↗
- Paper Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma ther… DOI 10.1039/d0nr03138k↗
- Paper Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic D… DOI 10.1002/advs.201902926↗
- Xin Zhang · 1 shared paper, 2026 · strength 0.32
- Huan Wang · 1 shared paper, 2025 · strength 0.18
- Xue Yang · 1 shared paper, 2025 · strength 0.18
- Tongsen Zheng · 1 shared paper, 2025 · strength 0.18
- Xianze Wang · 1 shared paper, 2025 · strength 0.18
- Qiang Xu · 1 shared paper, 2025 · strength 0.18
- Chuntao Gao · 1 shared paper, 2025 · strength 0.18
- Zhihua Li · 1 shared paper, 2025 · strength 0.18
- Tao Xia · 1 shared paper, 2025 · strength 0.18
- Yuejuan Cheng · 1 shared paper, 2025 · strength 0.18
- Heshui Wu · 1 shared paper, 2025 · strength 0.18
- Rufu Chen · 1 shared paper, 2025 · strength 0.18
- Deliang Fu · 1 shared paper, 2025 · strength 0.18
- Wenming Wu · 1 shared paper, 2025 · strength 0.18
- Zijun Xie · 2 shared papers, 2015–2020 · strength 0.16
- Zijun Li · 2 shared papers, 2015–2020 · strength 0.16
- Yin-Hao Shi · 1 shared paper, 2023 · strength 0.16
- Ying‐Qin Zhu · 1 shared paper, 2023 · strength 0.16
- Zhide Liu · 1 shared paper, 2023 · strength 0.16
- Qi Liu · 1 shared paper, 2023 · strength 0.16
- Ya-Xiong Li · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.